DrugCite
Search

STELARA

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Stelara Adverse Events Reported to the FDA Over Time

How are Stelara adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Stelara, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Stelara is flagged as the suspect drug causing the adverse event.

Most Common Stelara Adverse Events Reported to the FDA

What are the most common Stelara adverse events reported to the FDA?

Psoriasis
390 (3.47%)
Headache
244 (2.17%)
Myocardial Infarction
190 (1.69%)
Drug Ineffective
183 (1.63%)
Pneumonia
169 (1.5%)
Fatigue
137 (1.22%)
Dizziness
130 (1.16%)
Arthralgia
120 (1.07%)
Depression
120 (1.07%)
Cerebrovascular Accident
106 (.94%)
Cellulitis
105 (.93%)
Show More Show More
Dyspnoea
102 (.91%)
Off Label Use
99 (.88%)
Pruritus
88 (.78%)
Pyrexia
87 (.77%)
Nausea
75 (.67%)
Malaise
73 (.65%)
Psoriatic Arthropathy
70 (.62%)
Hypertension
68 (.6%)
Weight Decreased
67 (.6%)
Diarrhoea
66 (.59%)
Confusional State
64 (.57%)
Myalgia
64 (.57%)
Pustular Psoriasis
63 (.56%)
Vision Blurred
62 (.55%)
Lower Respiratory Tract Infection
61 (.54%)
Oedema Peripheral
61 (.54%)
Inappropriate Schedule Of Drug Admi...
59 (.52%)
Pain In Extremity
57 (.51%)
Arthritis
56 (.5%)
Blood Glucose Increased
56 (.5%)
Upper Respiratory Tract Infection
55 (.49%)
Rash
54 (.48%)
Oropharyngeal Pain
53 (.47%)
Staphylococcal Infection
53 (.47%)
Urinary Tract Infection
53 (.47%)
Anxiety
52 (.46%)
Back Pain
52 (.46%)
Death
52 (.46%)
Prostate Cancer
52 (.46%)
Asthenia
50 (.44%)
Chest Pain
50 (.44%)
Cough
50 (.44%)
Drug Dose Omission
50 (.44%)
Hepatic Enzyme Increased
50 (.44%)
Herpes Zoster
50 (.44%)
Bronchitis
49 (.44%)
Sepsis
49 (.44%)
Hypersensitivity
47 (.42%)
Nasopharyngitis
47 (.42%)
Visual Impairment
46 (.41%)
Pain
45 (.4%)
Fall
44 (.39%)
Convulsion
43 (.38%)
Weight Increased
43 (.38%)
Condition Aggravated
42 (.37%)
Diabetes Mellitus
42 (.37%)
Hyperhidrosis
40 (.36%)
Sinusitis
40 (.36%)
Squamous Cell Carcinoma
40 (.36%)
Therapeutic Response Decreased
40 (.36%)
Hepatic Function Abnormal
39 (.35%)
Urticaria
38 (.34%)
Vomiting
38 (.34%)
Blood Cholesterol Increased
37 (.33%)
Pulmonary Embolism
37 (.33%)
Renal Impairment
37 (.33%)
Asthma
36 (.32%)
Blood Pressure Increased
36 (.32%)
Gamma-glutamyltransferase Increased
36 (.32%)
Syncope
36 (.32%)
Gait Disturbance
35 (.31%)
Breast Cancer
34 (.3%)
Diverticulitis
32 (.28%)
Feeling Abnormal
31 (.28%)
Liver Function Test Abnormal
31 (.28%)
Abdominal Pain
30 (.27%)
Hepatic Steatosis
30 (.27%)
Anaemia
29 (.26%)
Infection
29 (.26%)
Lymphadenopathy
29 (.26%)
Renal Failure
29 (.26%)
Swelling
29 (.26%)
Atrial Fibrillation
28 (.25%)
B-cell Lymphoma
28 (.25%)
Cardiac Disorder
28 (.25%)
Chills
28 (.25%)
Liver Disorder
28 (.25%)
Multiple Sclerosis
28 (.25%)
Platelet Count Decreased
28 (.25%)
Balance Disorder
27 (.24%)
Cholecystitis
27 (.24%)
Guillain-barre Syndrome
27 (.24%)
Muscular Weakness
27 (.24%)
Amnesia
26 (.23%)
Osteomyelitis
26 (.23%)
Dysarthria
25 (.22%)
Guttate Psoriasis
25 (.22%)
Hepatic Neoplasm Malignant
25 (.22%)
Hospitalisation
25 (.22%)
Thrombocytopenia
25 (.22%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Stelara, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Stelara is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Stelara

What are the most common Stelara adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Stelara, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Stelara is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Stelara According to Those Reporting Adverse Events

Why are people taking Stelara, according to those reporting adverse events to the FDA?

Psoriasis
2737
Product Used For Unknown Indication
432
Psoriatic Arthropathy
94
Ill-defined Disorder
41
Drug Use For Unknown Indication
34
Pustular Psoriasis
29
Show More Show More
Crohns Disease
24
Dermatitis Atopic
10
Pyoderma Gangrenosum
9
Arthritis
9
Hidradenitis
6
Foetal Exposure During Pregnancy
5
Guttate Psoriasis
4
Erythrodermic Psoriasis
3
Exposure Via Semen
3
Nail Psoriasis
3
Drug Exposure During Pregnancy
2
Exposure Via Father
2
Maternal Exposure During Pregnancy
2
Autoimmune Disorder
2
Acute Febrile Neutrophilic Dermatos...
2
Sarcoidosis
1
Pityriasis Rubra Pilaris
1
Dermatitis Exfoliative
1
Respiratory Disorder
1
Pulmonary Embolism
1
Parapsoriasis
1
Rheumatoid Arthritis
1
Pyoderma
1
Systemic Lupus Erythematosus
1
Fistula
1

Drug Labels

LabelLabelerEffective
StelaraJanssen Biotech, Inc.18-APR-13

Stelara Case Reports

What Stelara safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Stelara. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Stelara.